The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
HIV-1 drug resistance and resistance testing
Open accessAbstract
The global scale-up of antiretroviral (ARV) therapy (ART) has led to dramatic reductions in HIV-1 mortality and incidence. However, HIV drug resistance (HIVDR) poses a potential threat to the long-term success of ART and is emerging as a threat to the elimination of AIDS as a public health problem by 2030. In this review we describe the genetic mechanisms, epidemiology, and management of HIVDR at both individual and population levels across diverse economic and geographic settings. To describe the genetic mechanisms of HIVDR, we review the genetic barriers to resistance for the most commonly used ARVs and describe the extent of cross-resistance between them. To describe the epidemiology of HIVDR, we summarize the prevalence and patterns of transmitted drug resistance (TDR) and acquired drug resistance (ADR) in both high-income and low- and middle-income countries (LMICs). We also review to two categories of HIVDR with important public health relevance: (i) pre-treatment drug resistance (PDR), a World Health Organization-recommended HIVDR surveillance metric and (ii) and pre-exposure prophylaxis (PrEP)-related drug resistance, a type of ADR that can impact clinical outcomes if present at the time of treatment initiation. To summarize the implications of HIVDR for patient management, we review the role of genotypic resistance testing and treatment practices in both high-income and LMIC settings. In high-income countries where drug resistance testing is part of routine care, such an understanding can help clinicians prevent virological failure and accumulation of further HIVDR on an individual level by selecting the most efficacious regimens for their patients. Although there is reduced access to diagnostic testing and to many ARVs in LMIC, understanding the scientific basis and clinical implications of HIVDR is useful in all regions in order to shape appropriate surveillance, inform treatment algorithms, and manage difficult cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
Coffin, J. M. (1995) · Science · doi:10.1126/science.7824947 · Cited by 1,981
Keele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S., Li, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802203105 · Cited by 1,912
UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1
&NA; (2001) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200106000-00020 · Cited by 1,660
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
Little, S. J., Holte, S., Routy, J.-P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013552 · Cited by 1,140
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
Fonner, V. A., Dalglish, S. L., Kennedy, C. E., Baggaley, R., O’Reilly, K. R., Koechlin, F. M., Rodolph, M., Hodges-Mameletzis, I., & Grant, R. M. (2016) · AIDS · doi:10.1097/qad.0000000000001145 · Cited by 993
Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update
Bennett, D. E., Camacho, R. J., Otelea, D., Kuritzkes, D. R., Fleury, H., Kiuchi, M., Heneine, W., Kantor, R., Jordan, M. R., Schapiro, J. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004724 · Cited by 938
Self-citationMaraviroc for Previously Treated Patients with R5 HIV-1 Infection
Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803152 · Cited by 752
Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex
Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G. W., Kufareva, I., Li, T., Ma, L., Fenalti, G., Li, J., et al. (2013) · Science · doi:10.1126/science.1241475 · Cited by 712
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A., Capon, D. J., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.920-928.2000 · Cited by 646
Raffi, F., Rachlis, A., Stellbrink, H.-J., Hardy, W. D., Torti, C., Orkin, C., Bloch, M., Podzamczer, D., Pokrovsky, V., Pulido, F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61853-4 · Cited by 548
Eron, J. J., Benoit, S. L., Jemsek, J., MacArthur, R. D., Santana, J., Quinn, J. B., Kuritzkes, D. R., Fallon, M. A., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332502 · Cited by 531
Molina, J.-M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., Moyle, G., Mancini, M., Percival, L., Yang, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61081-8 · Cited by 486
HIV-1 Drug Resistance in Newly Infected Individuals
Boden, D. (1999) · JAMA · doi:10.1001/jama.282.12.1135 · Cited by 466
Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons
Grant, R. M. (2002) · JAMA · doi:10.1001/jama.288.2.181 · Cited by 459
Dynamics of HIV-1 recombination in its natural target cells
Levy, D. N., Aldrovandi, G. M., Kutsch, O., & Shaw, G. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306764101 · Cited by 441
2015 update of the drug resistance mutations in HIV-1
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Jacobsen, D. M., Paredes, R., Shafer, R. W., & Richman, D. D. (2015) · PubMed · doi:10.5167/uzh-122257 · Cited by 415
Self-citationMolina, J.-M., Cahn, P., Grinsztejn, B., Lazzarin, A., Mills, A., Saag, M., Supparatpinyo, K., Walmsley, S., Crauwels, H., Rimsky, L. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60936-7 · Cited by 405
Cohen, C. J., Andrade-Villanueva, J., Clotet, B., Fourie, J., Johnson, M. A., Ruxrungtham, K., Wu, H., Zorrilla, C., Crauwels, H., Rimsky, L. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60983-5 · Cited by 374
Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID
Jabara, C. B., Jones, C. D., Roach, J., Anderson, J. A., & Swanstrom, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110064108 · Cited by 365
Gupta, R. K., Jordan, M. R., Sultan, B. J., Hill, A., Davis, D. H., Gregson, J., Sawyer, A. W., Hamers, R. L., Ndembi, N., Pillay, D., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61038-1 · Cited by 364
Self-citationWhitcomb, J. M., Huang, W., Fransen, S., Limoli, K., Toma, J., Wrin, T., Chappey, C., Kiss, L. D. B., Paxinos, E. E., & Petropoulos, C. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00853-06 · Cited by 356
Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P., Ciaramella, G., & Perros, M. (2007) · Journal of Virology · doi:10.1128/jvi.02006-06 · Cited by 350
Westby, M., Lewis, M., Whitcomb, J., Youle, M., Pozniak, A. L., James, I. T., Jenkins, T. M., Perros, M., & van der Ryst, E. (2006) · Journal of Virology · doi:10.1128/jvi.80.10.4909-4920.2006 · Cited by 337
Madruga, J. V., Berger, D., McMurchie, M., Suter, F., Banhegyi, D., Ruxrungtham, K., Norris, D., Lefebvre, E., de Béthune, M.-P., Tomaka, F., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61049-6 · Cited by 336
Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J.-M., Chas, J., Durant, J., Moreno, S., et al. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu051 · Cited by 333
HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications
Tang, M. W., & Shafer, R. W. (2012) · Drugs · doi:10.2165/11633630-000000000-00000 · Cited by 326
Self-citationEron, J. J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., Poizot-Martin, I., Richmond, G., Soriano, V., Ait-Khaled, M., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis750 · Cited by 311
Bennett, D. E., Myatt, M., Bertagnolio, S., Sutherland, D., & Gilks, C. F. (2008) · Antiviral Therapy · doi:10.1177/135965350801302s04 · Cited by 291
Self-citationHartley, O., Klasse, P. J., Sattentau, Q. J., & Moore, J. P. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.171 · Cited by 290
Modeling the within-host dynamics of HIV infection
Perelson, A. S., & Ribeiro, R. M. (2013) · BMC Biology · doi:10.1186/1741-7007-11-96 · Cited by 283
Brumme, Z. L., Goodrich, J., Mayer, H. B., Brumme, C. J., Henrick, B. M., Wynhoven, B., Asselin, J. J., Cheung, P. K., Hogg, R. S., Montaner, J. S. G., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/431519 · Cited by 270
Nature, Position, and Frequency of Mutations Made in a Single Cycle of HIV-1 Replication
Abram, M. E., Ferris, A. L., Shao, W., Alvord, W. G., & Hughes, S. H. (2010) · Journal of Virology · doi:10.1128/jvi.00915-10 · Cited by 267
Gregson, J., Tang, M., Ndembi, N., Hamers, R. L., Rhee, S.-Y., Marconi, V. C., Diero, L., Brooks, K. A., Theys, K., Rinke de Wit, T., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00536-8 · Cited by 267
Self-citationGupta, R. K., Hill, A., Sawyer, A. W., Cozzi-Lepri, A., von Wyl, V., Yerly, S., Lima, V. D., Günthard, H. F., Gilks, C., & Pillay, D. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70136-7 · Cited by 254
Little, S. J., Frost, S. D. W., Wong, J. K., Smith, D. M., Pond, S. L. K., Ignacio, C. C., Parkin, N. T., Petropoulos, C. J., & Richman, D. D. (2008) · Journal of Virology · doi:10.1128/jvi.02579-07 · Cited by 251
Weinstock, H. S., Zaidi, I., Heneine, W., Bennett, D., Garcia‐Lerma, J. G., Douglas, Jr., LaLota, M., Dickinson, G., Schwarcz, S., Torian, L., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/420789 · Cited by 246
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture
Brenner, B. G., Oliveira, M., Doualla-Bell, F., Moisi, D. D., Ntemgwa, M., Frankel, F., Essex, M., & Wainberg, M. A. (2006) · AIDS · doi:10.1097/01.aids.0000232228.88511.0b · Cited by 226
Rhee, S.-Y., Blanco, J. L., Jordan, M. R., Taylor, J., Lemey, P., Varghese, V., Hamers, R. L., Bertagnolio, S., de Wit, T. F. R., Aghokeng, A. F., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001810 · Cited by 223
Self-citationHIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
Blanco, J.-L., Varghese, V., Rhee, S.-Y., Gatell, J. M., & Shafer, R. W. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir025 · Cited by 218
Self-citationWinters, M. A., Coolley, K. L., Girard, Y. A., Levee, D. J., Hamdan, H., Shafer, R. W., Katzenstein, D. A., & Merigan, T. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci4948 · Cited by 216
Self-citationWhitcomb, J. M., Parkin, N. T., Chappey, C., Hellmann, N. S., & Petropoulos, C. J. (2003) · The Journal of Infectious Diseases · doi:10.1086/378281 · Cited by 216
HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
Rhee, S.-Y., Taylor, J., Fessel, W. J., Kaufman, D., Towner, W., Troia, P., Ruane, P., Hellinger, J., Shirvani, V., Zolopa, A., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00574-10 · Cited by 216
Self-citationWheeler, W. H., Ziebell, R. A., Zabina, H., Pieniazek, D., Prejean, J., Bodnar, U. R., Mahle, K. C., Heneine, W., Johnson, J. A., & Hall, H. I. (2010) · AIDS · doi:10.1097/qad.0b013e3283388742 · Cited by 213
Rockstroh, J. K., DeJesus, E., Lennox, J. L., Yazdanpanah, Y., Saag, M. S., Wan, H., Rodgers, A. J., Walker, M. L., Miller, M., DiNubile, M. J., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31828ace69 · Cited by 212
Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa
Paton, N. I., Kityo, C., Hoppe, A., Reid, A., Kambugu, A., Lugemwa, A., van Oosterhout, J. J., Kiconco, M., Siika, A., Mwebaze, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311274 · Cited by 202
Hamers, R. L., Schuurman, R., Sigaloff, K. C., Wallis, C. L., Kityo, C., Siwale, M., Mandaliya, K., Ive, P., Botes, M. E., Wellington, M., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70255-9 · Cited by 190
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome
Rosenbloom, D. I. S., Hill, A. L., Rabi, S. A., Siliciano, R. F., & Nowak, M. A. (2012) · Nature Medicine · doi:10.1038/nm.2892 · Cited by 189
Vingerhoets, J., Tambuyzer, L., Azijn, H., Hoogstoel, A., Nijs, S., Peeters, M., de Béthune, M.-P., De Smedt, G., Woodfall, B., & Picchio, G. (2010) · AIDS · doi:10.1097/qad.0b013e32833677ac · Cited by 185
Wilkin, T. J., Su, Z., Kuritzkes, D. R., Hughes, M., Flexner, C., Gross, R., Coakley, E., Greaves, W., Godfrey, C., Skolnik, P. R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511035 · Cited by 183
Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis Tool
Woods, C. K., Brumme, C. J., Liu, T. F., Chui, C. K. S., Chu, A. L., Wynhoven, B., Hall, T. A., Trevino, C., Shafer, R. W., & Harrigan, P. R. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06689-11 · Cited by 182
Self-citationWheeler, Ziebell, Zabina, & Pieniazek (2010) · AIDS · Cited by 182
Kuritzkes, D. R., Quinn, J. B., Benoit, S. L., Shugarts, D. L., Griffin, A., Bakhtiari, M., Poticha, D., Eron, J. J., Fallon, M. A., & Rubin, M. (1996) · AIDS · doi:10.1097/00002030-199610090-00007 · Cited by 177
Human Immunodeficiency Virus gag and protease: partners in resistance
Fun, A., Wensing, A. M. J., Verheyen, J., & Nijhuis, M. (2012) · Retrovirology · doi:10.1186/1742-4690-9-63 · Cited by 174
Rimsky, L., Vingerhoets, J., Van Eygen, V., Eron, J., Clotet, B., Hoogstoel, A., Boven, K., & Picchio, G. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31823df4da · Cited by 173
Ajose, O., Mookerjee, S., Mills, E. J., Boulle, A., & Ford, N. (2012) · AIDS · doi:10.1097/qad.0b013e328351f5b2 · Cited by 172
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors
Sluis-Cremer, N., & Tachedjian, G. (2008) · Virus Research · doi:10.1016/j.virusres.2008.01.002 · Cited by 172
(2013) · The Lancet · doi:10.1016/s0140-6736(13)61164-2 · Cited by 169
Larder, B. A. (1994) · Journal of General Virology · doi:10.1099/0022-1317-75-5-951 · Cited by 166
Viral Load Monitoring as a Tool to Reinforce Adherence: A Systematic Review
Bonner, K., Mezochow, A. K., Roberts, T., Ford, N. P., & Cohn, J. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31829f05ac · Cited by 165
Castagna, A., Danise, A., Menzo, S., Galli, L., Gianotti, N., Carini, E., Boeri, E., Galli, A., Cernuschi, M., Hasson, H., et al. (2006) · AIDS · doi:10.1097/01.aids.0000218542.08845.b2 · Cited by 165
Frost, S. D. W., Nijhuis, M., Schuurman, R., Boucher, C. A. B., & Brown, A. J. L. (2000) · Journal of Virology · doi:10.1128/jvi.74.14.6262-6268.2000 · Cited by 161
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance
Rabi, S. A., Laird, G. M., Durand, C. M., Laskey, S. B., Shan, L., Bailey, J. R., Chioma, S., Moore, R. D., & Siliciano, R. F. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67399 · Cited by 159
Waning, B., Diedrichsen, E., & Moon, S. (2010) · Journal of the International AIDS Society · doi:10.1186/1758-2652-13-35 · Cited by 154
Hunt, P. W., Harrigan, P. R., Huang, W., Bates, M. P., Williamson, D. W., McCune, J. M., Price, R. W., Spudich, S., Lampiris, H. W., Hoh, R., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/507312 · Cited by 146
Melikian, G., Rhee, S., Varghese, V., Porter, D., White, K., Taylor, J., Towner, W. J., Troia-Cancio, P. V., Burack, J. H., DeJesus, E., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt316 · Cited by 145
Self-citationForward Mutation Rate of Human Immunodeficiency Virus Type 1 in a T Lymphoid Cell Line*
Mansky, L. M. (1996) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1996.12.307 · Cited by 142
Marcelin, A., Delaugerre, C., Wirden, M., Viegas, P., Simon, A., Katlama, C., & Cálvez, V. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10550 · Cited by 136
Parikh, U. M., Bacheler, L. T., Koontz, D. L., & Mellors, J. W. (2006) · Journal of Virology · doi:10.1128/jvi.80.10.4971-4977.2006 · Cited by 130
Cozzi‐Lepri, A., Noguera-Julián, M., Giallonardo, F. D., Schuurman, R., Däumer, M., Aitken, S., Ceccherini‐Silberstein, F., Monforte, A. D., Geretti, A. M., Booth, C. L., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku426 · Cited by 130
Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug‐Resistant HIV‐1 Infection
Campbell, T., Shulman, N. S., Johnson, S. C., Zolopa, A. R., Young, R. K., Bushman, L. R., Fletcher, C. V., Lanier, E. R., Merigan, T. C., & Kuritzkes, D. R. (2005) · Clinical Infectious Diseases · doi:10.1086/430709 · Cited by 124
Kempf, D. J., Isaacson, J. D., King, M. S., Brun, S. C., Sylte, J., Richards, B., Bernstein, B. M., Rode, R. A., & Sun, E. (2002) · Antiviral Therapy · doi:10.1177/135965350200700305 · Cited by 123
Abram, M. E., Hluhanich, R. M., Goodman, D. D., Andreatta, K. N., Margot, N., Ye, L., Niedziela‐Majka, A., Barnes, T. L., Novikov, N. Y., Chen, X., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02568-12 · Cited by 121
Melby, T., DeSpirito, M., DeMasi, R., Heilek‐Snyder, G., Greenberg, M. L., & Graham, N. (2006) · The Journal of Infectious Diseases · doi:10.1086/504693 · Cited by 112
HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
Rhee, S., Sankaran, K., Varghese, V., Winters, M. A., Hurt, C. B., Eron, J. J., Parkin, N. T., Holmes, S., Holodniy, M., & Shafer, R. W. (2016) · Journal of Virology · doi:10.1128/jvi.00495-16 · Cited by 110
Self-citationNijhuis, M., Schuurman, R., de Jong, D. C. M., van Leeuwen, R., Lange, J. M. A., Danner, S. A., Keulen, W., de Groot, T. M., & Boucher, C. A. (1997) · The Journal of Infectious Diseases · doi:10.1086/514056 · Cited by 105
González‐Serna, A., Min, J. E., Woods, C. K., Chan, D., Lima, V., Montaner, J. S. G., Harrigan, P. R., & Swenson, L. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu019 · Cited by 101
Oette, M., Kaiser, R., Däumer, M., Petch, R., Fätkenheuer, G., Carls, H., Rockstroh, J. K., Schmalöer, D., Stechel, J., Feldt, T., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000214805.52723.c1 · Cited by 100
Rhee, S., Jordan, M. R., Raizes, E. G., Chua, A., Parkin, N. T., Kantor, R., van Zyl, G. U., Mukui, I., Hosseinipour, M. C., Frenkel, L. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145772 · Cited by 99
Self-citationFoulkes-Murzycki, J. E., Scott, W. R. P., & Schiffer, C. A. (2007) · Structure · doi:10.1016/j.str.2007.01.006 · Cited by 96
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1
Whitcomb, J. M., Huang, W., Limoli, K. L., Paxinos, E. E., Wrin, T., Skowron, G., Deeks, S. G., Bates, M. P., Hellmann, N. S., & Petropoulos, C. J. (2002) · AIDS · doi:10.1097/00002030-200210180-00002 · Cited by 96
Goodman, D. D., Zhou, Y., Margot, N., McColl, D. J., Zhong, L., Borroto–Esoda, K., Miller, M. D., & Svarovskaia, E. S. (2010) · AIDS · doi:10.1097/qad.0b013e3283427dcb · Cited by 96
Varghese, V., Shahriar, R., Rhee, S., Liu, T. F., Simen, B. B., Egholm, M., Hanczaruk, B., Blake, L. A., Gharizadeh, B., Babrzadeh, F., et al. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181bca669 · Cited by 96
Self-citationMolecular Impact of the M184V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase
Diallo, K., Götte, M., & Wainberg, M. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3377-3383.2003 · Cited by 93
Santoro, M. M., Fabeni, L., Armenia, D., Alteri, C., Pinto, D. D., Forbici, F., Bertoli, A., Carlo, D. D., Gori, C., Carta, S., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu020 · Cited by 90
Poveda, E., Briz, V., Quiñones‐Mateu, M. E., & Soriano, V. (2006) · AIDS · doi:10.1097/01.aids.0000233569.74769.69 · Cited by 87
Doyle, T., Dunn, D. T., Ceccherini‐Silberstein, F., de Mendoza, C., Garcia, F., Smit, E., Fearnhill, E., Marcelin, A., Martínez‐Picado, J., Kaiser, R., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv243 · Cited by 85
Use of Four Next-Generation Sequencing Platforms to Determine HIV-1 Coreceptor Tropism
Archer, J. P., Weber, J., Henry, K., Winner, D., Gibson, R. M., Lee, L., Paxinos, E. E., Arts, E. J., Robertson, D. L., Mimms, L. T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049602 · Cited by 83
Emerging patterns and implications of HIV-1 integrase inhibitor resistance
Geretti, A. M., Armenia, D., & Ceccherini‐Silberstein, F. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835a1de7 · Cited by 83
Swenson, L. C., Moores, A., Low, A., Thielen, A., Dong, W. W. Y., Woods, C. K., Jensen, M. A., Wynhoven, B., Chan, D., Glascock, C. B., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181d0558f · Cited by 81
Boyd, M. A., Moore, C. L., Molina, J., Wood, R., Madero, J. S., Wolff, M. J., Ruxrungtham, K., Losso, M. H., Renjifo, B., Teppler, H., et al. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(14)00061-7 · Cited by 79
HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial
Liegler, T. J., Abdel‐Mohsen, M., Bentley, L. G., Atchison, R. E., Schmidt, T. H., Javier, J., Mehrotra, M., Eden, C., Glidden, D. V., McMahan, V., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu233 · Cited by 77
Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays
Gupta, R. K., Kohli, A., McCormick, A. L., Towers, G. J., Pillay, D., & Parry, C. M. (2010) · AIDS · doi:10.1097/qad.0b013e3283398216 · Cited by 71
van Zyl, G. U., Liu, T. F., Claassen, M., Engelbrecht, S., de Oliveira, T., Preiser, W., Wood, N. T., Travers, S. A. A., & Shafer, R. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067188 · Cited by 67
Self-citationNucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins
Keulen, W., Boucher, C. A., & Berkhout, B. (1996) · Antiviral Research · doi:10.1016/0166-3542(96)00944-8 · Cited by 65
Invernizzi, C. F., Coutsinos, D., Oliveira, M., Moisi, D. D., BRENNER, B. G., & Wainberg, M. A. (2009) · The Journal of Infectious Diseases · doi:10.1086/605894 · Cited by 65
Stekler, J. D., McKernan, J. L., Milne, R. S., Tapia, K. A., Mykhalchenko, K., Holte, S., Maenza, J. R., Stevens, C. E., Buskin, S. E., Mullins, J. I., et al. (2014) · Antiviral Therapy · doi:10.3851/imp2780 · Cited by 64
Melikian, G., Rhee, S., Taylor, J., Fessel, W. J., Kaufman, D., Towner, W. J., Troia-Cancio, P. V., Zolopa, A. R., Robbins, G. K., Kagan, R. M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05487-11 · Cited by 63
Self-citationSluis‐Cremer, N., Jordan, M. R., Huber, K. D., Wallis, C. L., Bertagnolio, S., Mellors, J. W., Parkin, N. T., & Harrigan, P. R. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.04.001 · Cited by 62
Self-citationFourati, S., Charpentier, C., Amiel, C., Morand‐Joubert, L., Reigadas, S., Trabaud, M., Delaugerre, C., Nicot, F., Rodallec, A., Maillard, A. M., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku535 · Cited by 60
Scherrer, A., Ledergerber, B., von Wyl, V., Böni, J., Yerly, S., Klimkait, T., Bürgisser, P., Rauch, A., Hirschel, B. J., Cavassini, M. L., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir669 · Cited by 58
HIV Drug Resistance Testing by High-Multiplex “Wide” Sequencing on the MiSeq Instrument
Lapointe, H. R., Dong, W. W. Y., Lee, G. Q., Bangsberg, D. R., Martin, J. N., Mocello, A. R., Boum, Y., Karakas, A., Kirkby, D., Poon, A. F. Y., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01490-15 · Cited by 57
Recent trends in HIV-1 drug resistance
Siliciano, J. D., & Siliciano, R. F. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.08.007 · Cited by 54
Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC
Kassaye, S., Grossman, Z., Balamane, M., Johnston-White, B., Liu, C., Kumar, P. N., Young, M., Sneller, M. C., Sereti, I., Dewar, R. L., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw382 · Cited by 52
Self-citationKeys, J., Zhou, S., Anderson, J. A., Eron, J. J., Tompkins, L. A. R., Jabara, C. B., & Swanstrom, R. I. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.0031 · Cited by 46
Naeger, L. K., & Struble, K. A. (2006) · AIDS · doi:10.1097/01.aids.0000218548.77457.76 · Cited by 46
Phillips, A. N., Cambiano, V., Nakagawa, F., Magubu, T., Miners, A. H., Ford, D., Pillay, D., Luca, A. D., Lundgren, J. D., & Revill, P. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109148 · Cited by 46
Skhosana, L., Steegen, K., Bronze, M., Lukhwareni, A., Letsoalo, E., Papathanasopoulos, M. A., Carmona, S., & Stevens, W. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118145 · Cited by 42
Bartlett, J. A., Ribaudo, H. J., Wallis, C. L., Aga, E., Katzenstein, D. A., Stevens, W. S., Norton, M. R., Klingman, K. L., Hosseinipour, M. C., Crump, J. A., et al. (2012) · AIDS · doi:10.1097/qad.0b013e328353b066 · Cited by 41
Borroto–Esoda, K., Waters, J. M., Bae, A. S., Harris, J. L., Hinkle, J. E., Quinn, J., & Rousseau, F. (2007) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2006.0310 · Cited by 41
Jiang, X., Feyertag, F., Meehan, C. J., McCormack, G. P., Travers, S. A. A., Craig, C., Westby, M., Lewis, M., & Robertson, D. L. (2015) · Journal of Virology · doi:10.1128/jvi.01384-15 · Cited by 39
Theys, K., Vercauteren, J., Snoeck, J., Zazzi, M., Camacho, R. J., Torti, C., Schulter, E., Clotet, B., Sönnerborg, A. B., Luca, A. D., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01668-12 · Cited by 39
Levison, J. H., Wood, R., Scott, C. A., Ciaranello, A. L., Martinson, N. A., Rusu, C. A., Losina, E., Freedberg, K. A., & Walensky, R. P. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis887 · Cited by 33
Shahriar, R., Rhee, S., Liu, T. F., Fessel, W. J., Scarsella, A., Towner, W. J., Holmes, S., Zolopa, A. R., & Shafer, R. W. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00592-09 · Cited by 33
Self-citationHuang, W., Frantzell, A., Fransen, S., & Petropoulos, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00204-13 · Cited by 30
Chung, M. H., Beck, I. A., Dross, S., Tapia, K. A., Kiarie, J. N., Richardson, B. A., Overbaugh, J. M., Sakr, S. R., John-Stewart, G. C., & Frenkel, L. M. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000312 · Cited by 29
Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study
Guiguet, M., Ghosn, J., Duvivier, C., Meynard, J., Gras, G., Partisani, M., Teicher, E., Mahamat, A., Rodenbourg, F., Launay, O., et al. (2012) · AIDS · doi:10.1097/qad.0b013e32835646e0 · Cited by 28
Barber, T., Harrison, L., Asboe, D., Williams, I. G., Kirk, S., Gilson, R. J. C., Bansi‐Matharu, L., Pillay, D., & Dunn, D. T. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr569 · Cited by 27
Kulkarni, R., Abram, M. E., McColl, D. J., Barnes, T. L., Fordyce, M. W., Szwarcberg, J., Cheng, A., Miller, M. D., & White, K. (2014) · HIV Clinical Trials · doi:10.1310/hct1505-218 · Cited by 26
White, K., Raffi, F., & Miller, M. D. (2014) · Viruses · doi:10.3390/v6072858 · Cited by 25
Sutherland, K. A., Mbisa, J. L., Cane, P. A., Pillay, D., & Parry, C. M. (2013) · Journal of General Virology · doi:10.1099/vir.0.055624-0 · Cited by 22
Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
Collins, S. E., Grant, P., & Shafer, R. W. (2015) · Drugs · doi:10.1007/s40265-015-0515-6 · Cited by 22
Self-citationWhite, K., Kulkarni, R., McColl, D. J., et al. (2014) · Antiviral Therapy · doi:10.3851/imp2885 · Cited by 21
Mollan, K. R., Daar, E. S., Sax, P. E., Balamane, M., Collier, A. C., Fischl, M. A., Lalama, C. M., Bosch, R. J., Tierney, C., & Katzenstein, D. A. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis613 · Cited by 20
Buckton, A., Harris, R., Pillay, D., & Cane, P. A. (2010) · Antiviral Therapy · doi:10.3851/imp1687 · Cited by 19
Charest, H., Doualla‐Bell, F., Cantin, R., Murphy, D. G., Lemieux, L., BRENNER, B. G., Hardy, I., Moisi, D. D., Lo, E., Baril, J.-G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109420 · Cited by 18
Theys, K., Camacho, R. J., Gómes, P., Vandamme, A., & Rhee, S. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.02.011 · Cited by 15
Genetic Variability of HIV-1 for Drug Resistance Assay Development
Clutter, D. S., Sánchez, P., Rhee, S., & Shafer, R. W. (2016) · Viruses · doi:10.3390/v8020048 · Cited by 15
Self-citationHoffmann, C. J., Charalambous, S., Grant, A. D., Morris, L., Churchyard, G., & Chaisson, R. E. (2013) · Tropical Medicine & International Health · doi:10.1111/tmi.12237 · Cited by 10
Varghese, V., Pinsky, B. A., Smith, D. S., Klein, D., & Shafer, R. W. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2016.0038 · Cited by 7
Self-citation
Cited by
Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
McMillan, J., Szlachetka, A., Slack, L., Sillman, B., Lamberty, B., Morsey, B., Callen, S., Gautam, N., Alnouti, Y., Edagwa, B., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01316-17 · Cited by 32
Metadata
- Authors
- Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W.
- Venue
- Infection, Genetics and Evolution
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 46
- Pages
- 292-307
- ISSN
- 1567-1348 (ISSN-L)
- OpenAlex
- W2508295414
- Cited by
- 333
- References
- 132
- FWCI
- 21.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.